Zoetis (ZTS) Projected to Post Quarterly Earnings on Thursday

Zoetis (NYSE:ZTS) is projected to issue its Q4 2025 results before the market opens on Thursday, February 12th. Analysts expect the company to announce earnings of $1.40 per share and revenue of $2.3612 billion for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, February 12, 2026 at 8:30 AM ET.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, beating the consensus estimate of $1.62 by $0.08. The firm had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.42 billion. Zoetis had a return on equity of 57.19% and a net margin of 28.21%.Zoetis’s quarterly revenue was up .5% on a year-over-year basis. During the same period last year, the business posted $1.58 EPS. On average, analysts expect Zoetis to post $6 EPS for the current fiscal year and $7 EPS for the next fiscal year.

Zoetis Stock Performance

Shares of ZTS stock opened at $126.69 on Thursday. The stock has a fifty day moving average price of $124.00 and a 200 day moving average price of $136.62. The company has a debt-to-equity ratio of 1.31, a quick ratio of 2.28 and a current ratio of 3.64. The stock has a market cap of $55.83 billion, a PE ratio of 21.33, a P/E/G ratio of 2.11 and a beta of 0.96. Zoetis has a 1 year low of $115.25 and a 1 year high of $177.40.

Zoetis Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 3rd. Stockholders of record on Tuesday, January 20th will be paid a dividend of $0.53 per share. This is a boost from Zoetis’s previous quarterly dividend of $0.50. The ex-dividend date of this dividend is Tuesday, January 20th. This represents a $2.12 annualized dividend and a dividend yield of 1.7%. Zoetis’s dividend payout ratio is presently 35.69%.

Analyst Upgrades and Downgrades

ZTS has been the subject of several recent research reports. Piper Sandler restated a “neutral” rating and set a $135.00 target price (down from $190.00) on shares of Zoetis in a report on Thursday, January 22nd. HSBC set a $140.00 price objective on shares of Zoetis in a research note on Wednesday, December 10th. Bank of America lowered Zoetis from a “buy” rating to a “neutral” rating and set a $135.00 target price on the stock. in a research note on Monday, December 15th. Morgan Stanley set a $160.00 target price on Zoetis in a report on Thursday, December 18th. Finally, Weiss Ratings downgraded Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, January 28th. Five research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $152.45.

Institutional Trading of Zoetis

Several institutional investors have recently made changes to their positions in the stock. Bellevue Group AG grew its stake in shares of Zoetis by 32.7% in the third quarter. Bellevue Group AG now owns 872 shares of the company’s stock valued at $128,000 after buying an additional 215 shares in the last quarter. Newbridge Financial Services Group Inc. lifted its position in Zoetis by 23.7% during the 3rd quarter. Newbridge Financial Services Group Inc. now owns 1,145 shares of the company’s stock worth $168,000 after acquiring an additional 219 shares in the last quarter. Headlands Technologies LLC purchased a new position in Zoetis in the 2nd quarter worth approximately $194,000. Boothbay Fund Management LLC acquired a new stake in Zoetis in the second quarter valued at approximately $202,000. Finally, MUFG Securities EMEA plc purchased a new stake in shares of Zoetis during the second quarter valued at approximately $206,000. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.